Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BKD NASDAQ:CHRS NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBKDBrookdale Senior Living$13.33+0.6%$13.75$6.26▼$17.09$3.16B0.683.51 million shs3.31 million shsCHRSCoherus Oncology$1.51+2.0%$1.72$0.71▼$2.62$228.29M1.011.36 million shs701,778 shsTGTXTG Therapeutics$39.76+0.8%$34.81$25.28▼$44.65$6.04B1.682.31 million shs1.41 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBKDBrookdale Senior Living-0.68%+1.55%-4.06%-20.35%+95.48%CHRSCoherus Oncology-0.67%-13.45%-25.25%-9.20%+85.00%TGTXTG Therapeutics-0.13%-7.31%+11.60%+34.90%+12.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBKDBrookdale Senior Living$13.33+0.6%$13.75$6.26▼$17.09$3.16B0.683.51 million shs3.31 million shsCHRSCoherus Oncology$1.51+2.0%$1.72$0.71▼$2.62$228.29M1.011.36 million shs701,778 shsTGTXTG Therapeutics$39.76+0.8%$34.81$25.28▼$44.65$6.04B1.682.31 million shs1.41 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBKDBrookdale Senior Living-0.68%+1.55%-4.06%-20.35%+95.48%CHRSCoherus Oncology-0.67%-13.45%-25.25%-9.20%+85.00%TGTXTG Therapeutics-0.13%-7.31%+11.60%+34.90%+12.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBKDBrookdale Senior Living 2.71Moderate Buy$16.5023.83% UpsideCHRSCoherus Oncology 2.75Moderate Buy$8.67473.95% UpsideTGTXTG Therapeutics 2.57Moderate Buy$52.5032.04% UpsideCurrent Analyst Ratings BreakdownLatest BKD, TGTX, and CHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026CHRSCoherus Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/12/2026BKDBrookdale Senior Living Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/11/2026CHRSCoherus Oncology GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/11/2026CHRSCoherus Oncology GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/6/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $70.005/1/2026TGTXTG Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/1/2026TGTXTG Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/22/2026CHRSCoherus Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/21/2026BKDBrookdale Senior Living Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/20/2026BKDBrookdale Senior Living Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026BKDBrookdale Senior Living StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$18.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBKDBrookdale Senior Living$3.19B1.00$0.46 per share29.26($0.23) per share-57.93CHRSCoherus Oncology$42.17M5.52N/AN/A$0.51 per share2.96TGTXTG Therapeutics$616.29M9.88$2.83 per share14.07$3.81 per share10.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBKDBrookdale Senior Living-$262.69M-$0.86N/A83.28N/A-6.51%-15,050.32%-2.19%8/5/2026 (Estimated)CHRSCoherus Oncology$168.02M$1.670.90N/AN/A397.30%-198.90%-46.65%8/6/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8613.9014.30N/A65.95%88.73%43.44%8/3/2026 (Estimated)Latest BKD, TGTX, and CHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CHRSCoherus Oncology-$0.2633-$0.25+$0.0133-$0.28$14.22 million$12.31 million5/6/2026Q1 2026BKDBrookdale Senior Living-$0.0214-$0.03-$0.0086-$0.03$771.16 million$764.86 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million3/9/2026Q4 2025CHRSCoherus Oncology-$0.31-$0.34-$0.03-$0.31$14.09 million$12.75 million2/26/2026Q4 2025TGTXTG Therapeutics$0.35$0.14-$0.21$0.14$192.15 million$192.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBKDBrookdale Senior LivingN/AN/AN/AN/AN/ACHRSCoherus OncologyN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBKDBrookdale Senior LivingN/A1.031.03CHRSCoherus Oncology0.471.561.52TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBKDBrookdale Senior LivingN/ACHRSCoherus Oncology72.82%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipBKDBrookdale Senior Living1.80%CHRSCoherus Oncology8.08%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBKDBrookdale Senior Living36,000238.79 million234.49 millionOptionableCHRSCoherus Oncology330154.25 million141.79 millionOptionableTGTXTG Therapeutics290153.08 million136.80 millionOptionableBKD, TGTX, and CHRS HeadlinesRecent News About These CompaniesTGTX Stock Rises 29% in 3 Months: Here's What You Should KnowMay 20 at 11:56 AM | zacks.comTG Therapeutics (NASDAQ:TGTX) Shares Pass Above 200-Day Moving Average - Here's What HappenedMay 19 at 3:47 AM | americanbankingnews.comTG Therapeutics Stock Story Gains Interest In Nasdaq IndexMay 13, 2026 | kalkinemedia.comKTG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They AppearMay 13, 2026 | finance.yahoo.comHistoric Signal Says This Biotech OutperformsMay 11, 2026 | schaeffersresearch.comWhy TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI StrengthMay 11, 2026 | finance.yahoo.comAssessing TG Therapeutics (TGTX) Valuation After Recent Share Price MomentumMay 10, 2026 | finance.yahoo.comQ2 EPS Estimates for TG Therapeutics Increased by AnalystMay 8, 2026 | marketbeat.comTGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 ViewMay 7, 2026 | zacks.comTG Therapeutics Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comTG Therapeutics: Q1 Earnings SnapshotMay 6, 2026 | seattlepi.comSTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | markets.businessinsider.comTG Therapeutics (TGTX) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comTGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings missMay 6, 2026 | msn.comTG Therapeutics (NASDAQ:TGTX) Issues Quarterly Earnings ResultsMay 6, 2026 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Time to Buy?May 6, 2026 | marketbeat.comTG Therapeutics (TGTX) Q1 Earnings Lag EstimatesMay 6, 2026 | zacks.comVanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTXMay 6, 2026 | marketbeat.comTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | globenewswire.comTG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business UpdateApril 30, 2026 | globenewswire.comPictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTXApril 30, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 20263 European Bank Stocks Nearing New 52-Week HighsBy Dan Schmidt | April 27, 2026BKD, TGTX, and CHRS Company DescriptionsBrookdale Senior Living NYSE:BKD$13.32 +0.08 (+0.57%) Closing price 03:59 PM EasternExtended Trading$13.54 +0.21 (+1.61%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.Coherus Oncology NASDAQ:CHRS$1.51 +0.03 (+2.03%) Closing price 04:00 PM EasternExtended Trading$1.52 +0.01 (+0.66%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.TG Therapeutics NASDAQ:TGTX$39.76 +0.33 (+0.84%) Closing price 04:00 PM EasternExtended Trading$39.63 -0.13 (-0.33%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
